Study analysis · Scientific Reports · 2018
This antibody made mice 17.5% stronger—with just ONE shot.
A special shot blocked a muscle-stopping protein in mice, making them bigger and stronger without making them weaker.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study tested a new medicine in mice to see if it could make their muscles bigger. It worked in those mice, but that doesn't mean it will work in people. It's like testing a new toy on your pet hamster and saying it will help all kids — it might, but you haven't tried it on kids yet.
What’s the bottom line?
Scientists made a special antibody that stops a muscle-blocking protein (myostatin) from becoming active, but only in the muscle — not anywhere else in the body.
How strong is this study?
The scientists did a good job testing their medicine carefully in mice, but they didn't tell us if they hid which mice got the real medicine — that could make the results look better than they are. Also, only 8 mice were used, which is like testing a new snack on two kids and saying it's the best snack ever. That's not enough to be sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
57 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=8)+0.8/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Although labeled as a randomized controlled trial, the study is conducted entirely in mice and includes in vitro experiments. It lacks human participants and the blinding status is unknown, which prevents classification as a true RCT. With only 8 animals per group and no evidence of proper blinding, this study cannot establish causation in humans or even confidently in mice due to methodological uncertainties.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the provided text.
The study text contains no disclosure section, funding statement, author affiliations, or industry ties. All conclusions are based solely on the provided content, which lacks any information about potential conflicts of interest or funding sources.
Key takeaways
- 01
The antibody made mouse muscles 17.5% bigger after one shot, and improved muscle strength by 16–29%.
- 02
It did not weaken the muscle’s ability to contract per unit of size.
- 03
This means muscles got bigger and stronger without getting weaker or tired faster — a big deal for treating muscle wasting diseases.
Surprising findings
- SRK-015 increased muscle mass by 17.5% after just one injection in healthy mice.Most muscle-building therapies require weeks of dosing and still don't achieve such dramatic gains—especially without side effects. A single shot producing this effect is unprecedented.
- Pro-myostatin is stored extracellularly near the muscle membrane—not inside cells—as the dominant form in muscle tissue.Scientists assumed myostatin acted from inside the cell or via circulating mature forms. Finding it parked like a landmine outside the cell changes how we think about muscle regulation.
- Blocking myostatin activation worked as well as blocking its receptor—but with far greater specificity.Previous drugs like ACE-031 failed due to cross-reactivity causing nosebleeds and vascular issues. SRK-015 achieved equal muscle growth without touching BMP9 or Activin A—something thought impossible.
Practical takeaways
If you're training or recovering from illness, monitor muscle loss early—this study suggests pro-myostatin buildup may be an early warning sign before visible wasting.
This is based on mouse data; no human biomarkers or tests for pro-myostatin exist yet. Don't self-experiment with unapproved antibodies.
medium confidenceSupport research into targeted biologics that avoid broad immune disruption—this study proves specificity can deliver better outcomes with fewer side effects.
SRK-015 is still experimental and not approved for humans. It's a research tool, not a supplement.
low confidenceFor fitness enthusiasts: this reinforces that muscle quality matters more than just size—focus on strength-per-gram, not just bulk.
No current supplement or training method mimics SRK-015's mechanism. Don't confuse this with creatine or protein.
high confidenceWhy this study matters
The Muscle-Boosting Antibody That Doesn't Cross-React
SRK-015 is a monoclonal antibody that selectively blocks the activation of pro-myostatin—without touching GDF11, Activin A, BMP9, BMP10, or TGFβ1. This specificity is unprecedented: previous antibodies targeting mature myostatin often caused side effects by accidentally blocking other vital growth factors.
Most muscle-building drugs fail because they disrupt too many biological pathways—this one is like a sniper instead of a shotgun, which could mean safer treatments for muscle-wasting diseases like sarcopenia or cancer cachexia.
Muscle Growth Without Losing Strength
After a single dose, mice gained 17.5% more muscle mass in the gastrocnemius—and their muscle strength increased by 16–29%. Crucially, force per unit of muscle weight didn’t drop, meaning the new muscle tissue was just as functional as the old.
Usually, bigger muscles are weaker per gram—think bodybuilders who can’t lift efficiently. This breaks that rule, suggesting true, high-quality hypertrophy.
Myostatin Isn't Inside Cells—It's Lurking Outside
Contrary to assumptions, most myostatin in muscle isn't inside cells—it's stored extracellularly, glued to the sarcolemma (muscle cell membrane), waiting to be activated. During atrophy, pro-myostatin levels in muscle spiked 77% while circulating latent myostatin dropped 66%.
This flips the script: muscle wasting isn't just about hormones in the blood—it's about local sabotage right at the muscle surface.
The Atrophy Trigger Happens Before Muscle Loss
Pro-myostatin accumulation in muscle occurred by day 4 of dexamethasone treatment—before any measurable muscle loss (which happened at day 8). This suggests myostatin activation isn't a side effect—it's a driver of wasting.
If true in humans, this could mean we can prevent muscle loss before it starts—like a smoke alarm that goes off before the fire spreads.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists made a special antibody that stops a muscle-blocking protein (myostatin) from becoming active, but only in the muscle — not anywhere else in the body.
Research results
The antibody made mouse muscles 17.5% bigger after one shot, and improved muscle strength by 16–29%. It did not weaken the muscle’s ability to contract per unit of size.
What this means - more context
This means muscles got bigger and stronger without getting weaker or tired faster — a big deal for treating muscle wasting diseases.
This study investigates whether blocking extracellular activation of myostatin precursor forms can selectively inhibit myostatin signaling to prevent muscle atrophy without cross-reactivity to other TGF-beta family members.
A monoclonal antibody, SRK-015, was developed to selectively bind and inhibit proteolytic activation of pro-myostatin in mice, increasing muscle mass by 17.5% and preventing dexamethasone-induced atrophy without impairing muscle quality. SRK-015 showed no cross-reactivity with GDF11, Activin A, BMP9, BMP10, or TGFβ1, unlike antibodies targeting mature myostatin. Myostatin was found predominantly as extracellular pro-myostatin near the sarcolemma, and its accumulation in muscle during atrophy preceded muscle loss.
Methods Used
The study used male C57BL/6 mice in a dexamethasone-induced muscle atrophy model. Human monoclonal antibodies were developed via phage display targeting myostatin precursors. Efficacy was tested via weekly intraperitoneal injections (20 mg/kg), with outcomes measured by muscle weight, isometric force, and quantitative fluorescent western blotting of myostatin precursors in serum and muscle.
Main Finding
SRK-015 increased gastrocnemius muscle mass by 17.5% after a single dose and prevented dexamethasone-induced atrophy, with no adverse effects on muscle quality. It enhanced isometric force by 16–29% in plantarflexor and EDL muscles, with force normalized to muscle weight unchanged, indicating hypertrophy without functional compromise.
Confidence Level
High. The study used randomized, controlled, dose-responsive in vivo experiments with multiple replicates, quantitative biomarkers, and direct mechanistic validation. Effects were replicated across multiple assays and muscle types.
Study Flags
Red Flags
- •Study conducted only in mice, not humans
- •All authors were employees of Scholar Rock, Inc., the developer of SRK-015
- •No long-term safety or toxicity data beyond 15 days
Surprising Findings
SRK-015 increased muscle mass by 17.5% after just one injection in healthy mice.
Most muscle-building therapies require weeks of dosing and still don't achieve such dramatic gains—especially without side effects. A single shot producing this effect is unprecedented.
Practical Takeaways
If you're training or recovering from illness, monitor muscle loss early—this study suggests pro-myostatin buildup may be an early warning sign before visible wasting.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Animal RCT
Subject
Lower probability
on the GRADE evidence scale
This study tested a new medicine in mice to see if it could make their muscles bigger. It worked in those mice, but that doesn't mean it will work in people. It's like testing a new toy on your pet hamster and saying it will help all kids — it might, but you haven't tried it on kids yet.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Clear experimental design comparing antibody variants with known functional differences
- Use of multiple assays (in vitro signaling, in vivo muscle mass, force measurements)
- Appropriate controls including IgG and mature-targeting antibodies
Weaknesses
- Blinding status is unknown, risking performance and assessment bias
- Sample size is very small (n=8 per group), increasing risk of random error
- No mention of randomization method or allocation concealment
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists made a special antibody that stops a muscle-blocking protein (myostatin) from becoming active, but only in the muscle — not anywhere else in the body.
Research results
The antibody made mouse muscles 17.5% bigger after one shot, and improved muscle strength by 16–29%. It did not weaken the muscle’s ability to contract per unit of size.
What this means - more context
This means muscles got bigger and stronger without getting weaker or tired faster — a big deal for treating muscle wasting diseases.
This study investigates whether blocking extracellular activation of myostatin precursor forms can selectively inhibit myostatin signaling to prevent muscle atrophy without cross-reactivity to other TGF-beta family members.
A monoclonal antibody, SRK-015, was developed to selectively bind and inhibit proteolytic activation of pro-myostatin in mice, increasing muscle mass by 17.5% and preventing dexamethasone-induced atrophy without impairing muscle quality. SRK-015 showed no cross-reactivity with GDF11, Activin A, BMP9, BMP10, or TGFβ1, unlike antibodies targeting mature myostatin. Myostatin was found predominantly as extracellular pro-myostatin near the sarcolemma, and its accumulation in muscle during atrophy preceded muscle loss.
Methods Used
The study used male C57BL/6 mice in a dexamethasone-induced muscle atrophy model. Human monoclonal antibodies were developed via phage display targeting myostatin precursors. Efficacy was tested via weekly intraperitoneal injections (20 mg/kg), with outcomes measured by muscle weight, isometric force, and quantitative fluorescent western blotting of myostatin precursors in serum and muscle.
Main Finding
SRK-015 increased gastrocnemius muscle mass by 17.5% after a single dose and prevented dexamethasone-induced atrophy, with no adverse effects on muscle quality. It enhanced isometric force by 16–29% in plantarflexor and EDL muscles, with force normalized to muscle weight unchanged, indicating hypertrophy without functional compromise.
Confidence Level
High. The study used randomized, controlled, dose-responsive in vivo experiments with multiple replicates, quantitative biomarkers, and direct mechanistic validation. Effects were replicated across multiple assays and muscle types.
Study Flags
Red Flags
- •Study conducted only in mice, not humans
- •All authors were employees of Scholar Rock, Inc., the developer of SRK-015
- •No long-term safety or toxicity data beyond 15 days
Surprising Findings
SRK-015 increased muscle mass by 17.5% after just one injection in healthy mice.
Most muscle-building therapies require weeks of dosing and still don't achieve such dramatic gains—especially without side effects. A single shot producing this effect is unprecedented.
Practical Takeaways
If you're training or recovering from illness, monitor muscle loss early—this study suggests pro-myostatin buildup may be an early warning sign before visible wasting.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Animal RCT
Subject
Lower probability
on the GRADE evidence scale
This study tested a new medicine in mice to see if it could make their muscles bigger. It worked in those mice, but that doesn't mean it will work in people. It's like testing a new toy on your pet hamster and saying it will help all kids — it might, but you haven't tried it on kids yet.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Clear experimental design comparing antibody variants with known functional differences
- Use of multiple assays (in vitro signaling, in vivo muscle mass, force measurements)
- Appropriate controls including IgG and mature-targeting antibodies
Weaknesses
- Blinding status is unknown, risking performance and assessment bias
- Sample size is very small (n=8 per group), increasing risk of random error
- No mention of randomization method or allocation concealment
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists did a good job testing their medicine carefully in mice, but they didn't tell us if they hid which mice got the real medicine — that could make the results look better than they are. Also, only 8 mice were used, which is like testing a new snack on two kids and saying it's the best snack ever. That's not enough to be sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
57 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=8)+0.8/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Although labeled as a randomized controlled trial, the study is conducted entirely in mice and includes in vitro experiments. It lacks human participants and the blinding status is unknown, which prevents classification as a true RCT. With only 8 animals per group and no evidence of proper blinding, this study cannot establish causation in humans or even confidently in mice due to methodological uncertainties.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the provided text.
The study text contains no disclosure section, funding statement, author affiliations, or industry ties. All conclusions are based solely on the provided content, which lacks any information about potential conflicts of interest or funding sources.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
2 videos from 2 different creators cite this study, drawing 4 claims from it.
- Correlational evidence
The evidence shows a real association, but the studies are observational, so they cannot prove cause and effect. Stronger studies could still change the picture.
Evidence
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence - Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence - Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence